| ID Source | ID |
|---|---|
| PubMed CID | 4066056 |
| CHEMBL ID | 1539561 |
| CHEBI ID | 108175 |
| Synonym |
|---|
| AK-968/15359111 , |
| 2-chloro-n-(3-{4-[3-({2-chloro-5-nitrobenzoyl}amino)propyl]-1-piperazinyl}propyl)-5-nitrobenzamide |
| smr000227345 |
| MLS000702485 , |
| n,n'-(piperazine-1,4-diyldipropane-3,1-diyl)bis(2-chloro-5-nitrobenzamide) |
| STK421121 |
| CHEBI:108175 |
| AKOS003307606 |
| 2-chloro-n-[3-[4-[3-[(2-chloro-5-nitrobenzoyl)amino]propyl]piperazin-1-yl]propyl]-5-nitrobenzamide |
| HMS2542N20 |
| cid_4066056 |
| bdbm46306 |
| 2-chloro-n-[3-[4-[3-[(2-chloro-5-nitro-benzoyl)amino]propyl]piperazino]propyl]-5-nitro-benzamide |
| 2-chloro-n-[3-[4-[3-[[(2-chloro-5-nitrophenyl)-oxomethyl]amino]propyl]-1-piperazinyl]propyl]-5-nitrobenzamide |
| 2-chloranyl-n-[3-[4-[3-[(2-chloranyl-5-nitro-phenyl)carbonylamino]propyl]piperazin-1-yl]propyl]-5-nitro-benzamide |
| CHEMBL1539561 |
| Q27186837 |
| 2-chloro-n~1~-[3-(4-{3-[(2-chloro-5-nitrobenzoyl)amino]propyl}piperazino)propyl]-5-nitrobenzamide |
| Class | Description |
|---|---|
| organohalogen compound | A compound containing at least one carbon-halogen bond (where X is a halogen atom). |
| carbonyl compound | Any compound containing the carbonyl group, C=O. The term is commonly used in the restricted sense of aldehydes and ketones, although it actually includes carboxylic acids and derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 19.9526 | 0.0020 | 14.6779 | 39.8107 | AID1478 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 12.5893 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 25.1189 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 89.1251 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 12.5893 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| kallikrein-5 preproprotein | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 1.3592 | 11.3060 | 50.0000 | AID1431 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Bcl-2-like protein 10 | Homo sapiens (human) | EC50 (µMol) | 43.3600 | 1.4600 | 1.4600 | 1.4600 | AID1327 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| apoptotic process | Bcl-2-like protein 10 | Homo sapiens (human) |
| activation of cysteine-type endopeptidase activity involved in apoptotic process | Bcl-2-like protein 10 | Homo sapiens (human) |
| spermatogenesis | Bcl-2-like protein 10 | Homo sapiens (human) |
| female gamete generation | Bcl-2-like protein 10 | Homo sapiens (human) |
| microtubule organizing center organization | Bcl-2-like protein 10 | Homo sapiens (human) |
| negative regulation of apoptotic process | Bcl-2-like protein 10 | Homo sapiens (human) |
| intrinsic apoptotic signaling pathway in response to DNA damage | Bcl-2-like protein 10 | Homo sapiens (human) |
| extrinsic apoptotic signaling pathway in absence of ligand | Bcl-2-like protein 10 | Homo sapiens (human) |
| release of cytochrome c from mitochondria | Bcl-2-like protein 10 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| calcium ion binding | Bcl-2-like protein 10 | Homo sapiens (human) |
| protein binding | Bcl-2-like protein 10 | Homo sapiens (human) |
| caspase binding | Bcl-2-like protein 10 | Homo sapiens (human) |
| BH domain binding | Bcl-2-like protein 10 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| mitochondrion | Bcl-2-like protein 10 | Homo sapiens (human) |
| endoplasmic reticulum | Bcl-2-like protein 10 | Homo sapiens (human) |
| spindle | Bcl-2-like protein 10 | Homo sapiens (human) |
| cytosol | Bcl-2-like protein 10 | Homo sapiens (human) |
| membrane | Bcl-2-like protein 10 | Homo sapiens (human) |
| nuclear membrane | Bcl-2-like protein 10 | Homo sapiens (human) |
| mitochondria-associated endoplasmic reticulum membrane contact site | Bcl-2-like protein 10 | Homo sapiens (human) |
| mitochondrial outer membrane | Bcl-2-like protein 10 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||